• KOL
    • Autoimmune Pancreatitis
    • Shigeyuki Shigeyuki
    • Shigeyuki Shigeyuki: Influence Statistics

      Shigeyuki Shigeyuki

      Shigeyuki Shigeyuki

      Show email address

      Department of Internal Medicine, Matsumoto Dental University, Shiojiri, Japan | Department of Internal Medicine, Matsumoto Dental University, Shiojiri, Japan. Electronic ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Shigeyuki Shigeyuki:Expert Impact

      Concepts for whichShigeyuki Shigeyukihas direct influence:Autoimmune pancreatitis,Pancreatic cancer,Chronic pancreatitis,Autoimmune pancreatitis aip,Steroid therapy,Acute pancreatitis,School closure,Matsumoto city.

      Shigeyuki Shigeyuki:KOL impact

      Concepts related to the work of other authors for whichfor which Shigeyuki Shigeyuki has influence:Autoimmune pancreatitis,Pancreatic cancer,Igg4related disease,Immunoglobulin g4,Steroid therapy,Retroperitoneal fibrosis,Plasma cells.

      KOL Resume for Shigeyuki Shigeyuki

      Year
      2022

      Department of Internal Medicine, Matsumoto Dental University, Shiojiri, Japan

      2021

      Department of Internal Medicine, Matsumoto Dental University, Matsumoto, Japan

      2020

      Department of Internal Medicine, Matsumoto Dental University, Shiojiri, Nagano, Japan.

      2019

      Center for Health Safety and Environmental Management, Shinshu University, Matsumoto, Japan

      Department of Internal Medicine, Matsumoto Dental University, Shiojiri.

      2018

      Department of Internal Medicine, Matsumoto Dental University

      2017

      Center for Health, Safety, and Environmental Management, Shinshu University, Matsumoto, Japan

      2016

      Center for Health, Safety, and Environmental Management, Shinshu University School of Medicine, Matsumoto, Japan

      2015

      From the Department of Gastroenterology, the Endoscopic Examination Center, and the Center for Health, Safety, and Environmental Management, Shinshu University School of Medicine, Matsumoto, Japan.J. Asano, MD, Department of Gastroenterology, Shinshu University School of Medicine; T. Watanabe, MD, PhD, Department of Gastroenterology, Shinshu University School of Medicine; T. Oguchi, MD, Department of Gastroenterology, Shinshu University School of Medicine; K. Kanai, MD, Department of Gastroenterology, Shinshu University School of Medicine; M. Maruyama, MD, PhD, Department of Gastroenterology, Shinshu University School of Medicine; T. Ito, MD, PhD, Department of Gastroenterology, Shinshu University School of Medicine; T. Muraki, MD, PhD, Department of Gastroenterology, Shinshu University School of Medicine; H. Hamano, MD, PhD, Department of Gastroenterology, Shinshu University School of Medicine; N. Arakura, MD, PhD, Endoscopic Examination Center, Shinshu University School of Medicine; A. Matsumoto, MD, PhD, Department of Gastroenterology, Shinshu University School of Medicine; S. Kawa, MD, PhD, Center for Health, Safety, and Environmental Management, Shinshu University.

      Center for Health, Safety, and Environmental Management, Shinshu University, 3-1-1 Asahi, Matsumoto, 390-8621 Japan

      2014

      Shinshu University Center for Health, Safety and Environmental Management Matsumoto Japan

      2013

      Center for Health, Safety and Environment Management, Shinshu University, Japan

      2012

      Department of Medicine, Gastroenterology

      Center for Health, Safety and Environmental Management; Shinshu University; Matsumoto Japan

      2011

      Center for Health, Safety and Environmental Management, Shinshu University School of Medicine, Japan

      2010

      Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan

      2009

      Center for Health, Safety, and Environmental Management, Shinshu University School of Medicine

      2008

      *Center for Health, Safety and Environmental Management and †Department of Gastroenterology, Shinshu University School of Medicine, Nagano, Japan.

      Health, Safety and Environmental Management, Shinshu University

      2007

      *Kansai Medical University, Osaka; †Sinshu University, Nagano; ‡Tokyo Metropolitan Komagome Hospital, Tokyo; §Nagoya University, Nagoya; ∥Showa University, Tokyo; ¶Kochi Medical School, Kochi-Ken; #Nagoya City University, Nagoya; **Kyushu University, Fukuoka; ††Ogaki Municipal Hospital, Ogaki; ‡‡Fujita Health University, Aichi-Ken; §§Tohoku University, Sendai; ∥∥Kurihara Central Hospital, Kurihara; ¶¶Juntendo University, Tokyo; ##University of Occupational and Environmental Health, Fukuoka; ***Tokyo Women's Medical University, Tokyo; †††Chiba University, Chiba; ‡‡‡Kyorin University, Tokyo; and **Kyushu University, Fukuoka, Japan.

      Second Department of Internal Medicine, Shinshu University School of Medicine,

      2006

      Center for Health, Safety and Environmental Management, Shinshu University, Matsumoto 390-8621, Japan

      From the *Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi; †Department of Prevalence Medicine, Nagoya University School of Medicine, Nagoya; ‡Department of Medicine, Gastroenterology, Shinshu University School of Medicine, Matsumoto; §Second Department of Internal Medicine, Showa University School of Medicine, Tokyo; ∥Department of Gastroenterology, Toranomon Hospital, Tokyo; ¶Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo; #Department of Medicine and Clinical Oncology, Chiba University School of Medicine, Chiba; **Department of Gastroenterology, Faculty of Medicine, University of Tokyo, Tokyo; ††Department of Gastroenterology, Sapporo-kosei General Hospital, Sapporo; ‡‡Department of Gastroenterology, Asahikawa-kosei General Hospital, Asahikawa and §§Third Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu.

      Internal Medicine and

      2005

      Current affiliations: Department of Medicine, Gastroenterology, Department of Laboratory Medicine, Department of Surgery, Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan

      2004

      Current affiliations: Department of Medicine, Department of Laboratory Medicine, and Department of Endoscopy, Shinshu University School of Medicine, Matsumoto, Japan

      2003

      Second Department of Internal Medicine, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

      2002

      The Second Department of Medicine, Shinshu University School of Medicine

      2001

      Department of Internal Medicine, Showa Inan General Hospital, Komagane, and Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan

      Shinshu University Medical School

      2000

      From the Department of Pediatrics, Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto; Blood Transfusion Service, Shinshu University Hospital, Matsumoto; Research and Development, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc, Tokyo, Japan.

      The Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, USA

      Second Department of Internal Medicine and the First Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan

      1998

      Department of Internal Medicine, Kiso Prefectural Hospital, Kiso-Fukushima Japan

      1997

      Second Department of Internal Medicine, Shinshu University School of Medicine, 3‐1‐1 Asahi, Matsumoto 390, Japan. Fax: 81‐263‐32‐9412

      1996

      Second Department of Internal Medicine, Shinshu University, School of Medicine, Matsumoto, Japan

      1995

      Second Department of Internal Medicine, Shinshu University School of Medicine.

      1994

      Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan (Kawa) (Tokoo) (Oguchi) (Furuta) Cardiovascular Institute, Shinshu University School of Medicine, Matsumoto, Japan †Department of Transfusion Service, Shinshu University School of Medicine, Matsumoto, Japan ‡Sanyo Chemical Industries, Kyoto, Japan

      1993

      Second Dept. of Internal Medicine, Dept. of Laboratory Medicine, Cardiovascular Institute, Shinshu University School of Medicine, Matsumoto, Japan

      1992

      Dept. of Internal Medicine and Dept. of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto, Japan

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Shigeyuki Shigeyuki is among the top experts in the world.
      Concept World rank
      aip relapse risk #1
      aip iri #1
      lacking igg4 #1
      aipassociated prostatitis #1
      igg4rd immunoglobulin g4 #1
      vva higher affinity #1
      ca50 span1 #1
      cystrelated complications #1
      patient autoimmune pancreatitis #1
      igg4rd bhl #1
      biopsy lung nodule #1
      fibrotic pseudotumor #1
      sbmpd #1
      aip1 areas #1
      autoimmune pancreatitis relapse #1
      serum amylase concentration #1
      11year mikuliczs disease #1
      ca242 stagnation #1
      foxe1 tfpi2 #1
      autoimmune pancreatitis relationship #1
      95 mpd dilation #1
      igg4 aip1 #1
      sarcoidosis igg4 #1
      aip recurrence #1
      japan seasonal influenza #1
      serum levels ca50 #1
      hla drb10405dqb10401 alleles #1
      eswl chronic #1
      additional assay systems #1
      cyclin foxe1 #1
      aip relapse autoimmune #1
      2141 schoolchildren #1
      aip subgroups #1
      prednisolone recurrent attacks #1
      msf patient #1
      micro ouchterlony method #1
      relationship ski #1
      japan 2014 2015 #1
      matsumoto city #1
      pancreatic body progression #1
      patients suspected sarcoidosis #1
      ebs steroid #1
      techniques lewis tumorassociated #1
      periarteritis based #1
      orbit fibrosis #1
      school closure #1
      reproduction schoolchildren #1
      pancreatic juice ca19 #1
      levels ca50 #1
      diagnostic ability jps #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Shigeyuki Shigeyuki

      KOL-Index: 14619

      BACKGROUND: Sclerosing pancreatitis is a unique form of pancreatitis that is characterized by irregular narrowing of the main pancreatic duct, lymphoplasmacytic inflammation of the pancreas, and hypergammaglobulinemia and that responds to glucocorticoid treatment. Preliminary studies suggested that serum IgG4 concentrations are elevated in this disease but not in other diseases of the pancreas or biliary tract.

      METHODS: We measured serum IgG4 concentrations using single radial ...

      Known for Sclerosing Pancreatitis | Serum Igg4 Concentrations | Immune Complexes | Igg4 Subclass | Glucocorticoid Therapy
      KOL-Index: 14479

      A comparative study of a new tumour marker, CA242, and CA19-9 was conducted with special reference to their diagnostic usefulness in pancreatic cancer. CA242 showed sensitivity similar to that of CA19-9 for overall cases and early cases (stage I tumour) of pancreatic cancer. For other malignancies, the positive rates of CA242 were lower than those of CA19-9 except for colorectal cancer. An important characteristics of CA242 was that it was only slightly and infrequently elevated in the ...

      Known for Pancreatic Cancer | Ca242 Ca19 | Sensitivity Specificity | Carbohydrate Biomarkers | Chronic Pancreatitis
      KOL-Index: 13112

      OBJECTIVE: The aim of this study was to estimate the number of autoimmune pancreatitis (AIP) patients in Japan and evaluate the influence of steroid therapy on the course of diabetes mellitus (DM) in AIP.

      METHODS: A total of 2972 departments were randomly selected with hospital stratification throughout Japan. We sent a questionnaire asking the selected departments to report the number of patients who had visited their hospital in 2002 and who fulfilled the diagnostic criteria for AIP ...

      Known for Steroid Therapy | Autoimmune Pancreatitis | Dm Aip | Diabetes Mellitus | Cortex Hormones
      KOL-Index: 12511

      INTRODUCTION: Ligand activation of peroxisome proliferator-activated receptor gamma (PPAR gamma) results in growth inhibition and differentiation of various cancer cells.

      AIMS: We determined whether the PPAR gamma ligand, troglitazone, inhibits the growth of pancreatic cancer cells and clarified the underlying mechanisms with a special focus on restriction point control of the late G1 phase of the cell cycle.

      METHODOLOGY: Nine pancreatic cancer cell lines were used to study a variety of ...

      Known for Growth Inhibition | Pancreatic Cancer | Cell Lines | Ligand Troglitazone | Ppar Gamma
      KOL-Index: 11697

      BackgroundFluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been widely used for the diagnosis of pancreatic cancer. Because autoimmune pancreatitis is easily misdiagnosed as pancreatic cancer and can be tested for by FDG-PET analysis based on the presence of suspected pancreatic cancer, we attempted to clarify the differences in FDG-PET findings between the two conditions.MethodsWe compared FDG-PET findings between 15 patients with autoimmune pancreatitis and 26 ...

      Known for Autoimmune Pancreatitis | Pancreatic Cancer | Emission Tomography | Fluorodeoxyglucose Positron | Fdg Pet
      KOL-Index: 11306

      Steroid therapy appeared to be a standard treatment for autoimmune pancreatitis (AIP), although some AIP patients improve spontaneously. The indications for steroid therapy in AIP patients are symptoms such as obstructive jaundice, abdominal pain, and back pain, and the presence of symptomatic extrapancreatic lesions. Before steroid therapy, jaundice should be managed by biliary drainage in patients with obstructive jaundice, and blood glucose levels should be controlled in patients with ...

      Known for Autoimmune Pancreatitis | Steroid Therapy | Aip Patients | Obstructive Jaundice | Dose Maintenance Dose
      KOL-Index: 11155

      As the number of patients with autoimmune pancreatitis (AIP) is increasing in Japan, practical guidelines for managing AIP need to be established. Three committees [the professional committee for developing clinical questions (CQs) and statements by Japanese specialists, the expert panelist committee for rating statements by the modified Delphi method, and the evaluating committee of moderators] were organized. Fifteen AIP specialists extracted specific clinical statements from a total ...

      Known for Autoimmune Pancreatitis | Japanese Consensus | Cqs Statements | Professional Committee | Differential Diagnosis
      KOL-Index: 11146

      To obtain information regarding the growth-inhibitory effect of 1,25-dihydroxyvitamin D3 and its non-calcaemic analogue 22-oxa-1,25-dihydroxyvitamin D3 on pancreatic cancer cell lines, differences in the effects of G1-phase cell cycle-regulating factors were studied in vitamin D-responsive and non-responsive cell lines. Levels of expression of cyclins (D1, E and A), cyclin-dependent kinases (2 and 4) and cyclin-dependent kinase inhibitors (p21 and p27) were analysed by Western blotting ...

      Known for Growth Inhibition | Cell Lines | P21 P27 | Cyclin Dependent | Kinase Inhibitor
      KOL-Index: 10685

      BACKGROUND: Ligand activation of peroxisome proliferator-activated receptor gamma (PPARgamma) results in the inhibition of proliferation of various cancer cells. The aim of this study is to investigate the mechanisms of cell growth inhibition of hepatocellular carcinoma (HCC) cell lines by the PPARgamma ligand, troglitazone.

      METHODS: Six HCC cell lines were used to study the effects of troglitazone on cell growth by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) ...

      Known for Hepatocellular Carcinoma | Cell Lines | Growth Inhibition | Ligand Troglitazone | Flow Cytometry
      KOL-Index: 10420

      BackgroundAutoimmune pancreatitis is a unique form of chronic pancreatitis characterized by high serum IgG4 concentrations and abundant IgG4-bearing plasma cell infiltration in the pancreatic lesion, and it has been reported to be associated with a variety of extrapancreatic lesions, leading us to postulate the concept of a systemic inflammatory disease. To confirm this, we clarified the exact distribution of these extrapancreatic lesions and provide a panoramic view of them.MethodsThe ...

      Known for Extrapancreatic Lesions | Chronic Pancreatitis | Systemic Inflammatory Disease | Characteristic Findings | Corticosteroid Therapy
      KOL-Index: 10410

      BACKGROUND & AIMS: Autoimmune pancreatitis is a distinctive disease entity characterized by high serum immunoglobulin G4 concentrations. Because of the close association between some autoimmune diseases and particular alleles of major histocompatibility complex genes, we investigated the association between HLA alleles and autoimmune pancreatitis.

      METHODS: HLA-A, -B, -C, -DR, and -DQ gene typing and HLA-DRB1, -DQB1, and -DPB1 allele typing were performed by the polymerase chain reaction ...

      Known for Autoimmune Pancreatitis | Japanese Population | Hla Drb10405 | Dqb10401 Haplotype | 40 Patients
      KOL-Index: 10281

      We examined the effects of retinoids on the human mast cell development using a serum-deprived culture system. When 10-week cultured mast cells derived from CD34(+) cord blood cells were used as target cells, both all-trans retinoic acid (ATRA) and 9-cis RA inhibited the progeny generation under stimulation with stem cell factor (SCF) in a dose-dependent manner (the number of progeny grown by SCF plus RA at 10(-7) mol/L was one tenth of the value obtained by SCF alone). The early steps ...

      Known for Mast Cell | Retinoic Acid | Cord Blood | Factor Scf | Retinoid Receptors
      KOL-Index: 10255

      In 2002, the Japan Pancreas Society (JPS) was the first in the world to propose diagnostic criteria for autoimmune pancreatitis (AIP). Since the concept of AIP has changed with the accumulation of AIP cases, the Research Committee of Intractable Pancreatic Diseases (RCIPD) provided by the Ministry of Health, Labour and Welfare of Japan and the JPS issued revised clinical diagnostic criteria of AIP in 2006. The Asan Medical Center of Korea also proposed diagnostic criteria for AIP in ...

      Known for Autoimmune Pancreatitis | Diagnostic Criteria Aip | Imaging Studies | Pancreatobiliary Diseases | Japan Pancreas Society
      KOL-Index: 10173

      Measures of seasonal influenza control are generally divided into two categories: pharmaceutical and non-pharmaceutical interventions. The effectiveness of these measures remains unclear, because of insufficient study sample size and/or differences in study settings. This observational epidemiological study involved all elementary schoolchildren in Matsumoto City, Japan, with seasonal influenza during the 2014/2015 season. Questionnaires, including experiences with influenza diagnosis ...

      Known for Matsumoto City | Seasonal Influenza | Elementary Schoolchildren | Effectiveness Masks | Hand Washing

      Key People For Autoimmune Pancreatitis

      Top KOLs in the world
      #1
      Kazuichi Okazaki
      autoimmune pancreatitis pancreatic cancer igg4related disease
      #2
      Shigeyuki Shigeyuki
      autoimmune pancreatitis pancreatic cancer steroid therapy
      #3
      Terumi Kamisawa
      autoimmune pancreatitis pancreaticobiliary maljunction pancreatic duct
      #4
      Suresh T Chari
      pancreatic cancer autoimmune pancreatitis early detection
      #5
      Hideaki Hamano
      autoimmune pancreatitis pancreatic cancer steroid therapy
      #6
      Keiko Shiratori
      autoimmune pancreatitis pancreatic secretion nonalcoholic steatohepatitis

      Department of Internal Medicine, Matsumoto Dental University, Shiojiri, Japan | Department of Internal Medicine, Matsumoto Dental University, Shiojiri, Japan. Electronic address: shigeyuki.kawa@mdu.ac.jp. | Department of Internal Medicine Matsumoto D

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.